VivoSeq
Explore
Companies
Drugs
Sign In
Report Error
CTx-1301 - Dexmethylphenidate
Phase 3
Small molecule
C
Cingulate Therapeutics
1
Indications
2
Total Trials
0
Active Trials
0
Competitors
Pipeline
Status by Indication
[3]
[1]
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
ADHD
Completed
Preclinical
Phase 1
Phase 2
Phase 3
Approved
ADHD
Phase 3
Completed
Clinical
Trials by Indication
[1]
Efficacy and Safety
1 trial
Phase 3 Efficacy and Safety Laboratory Classroom Study in Pediatrics (6-12) With ADHD Using CTx-1301
Suspended
·
C
Cingulate Therapeutics
·
Phase 3
·
NCT05924594
·
45 enrolled
ADHD
1 trial
A Phase 3, Dose-Optimized, Randomized, Double-Blind, Placebo-Controlled, Single-Center, Parallel Efficacy and Safety Laboratory Classroom Study in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD) Using CTx-1301 (Dexmethylphenidate)
Completed
·
C
Cingulate Therapeutics
·
Phase 3
·
NCT05631626
·
26 enrolled
Sources
References
[1]
ClinicalTrials.gov
—
2 trial records for CTx-1301 - Dexmethylphenidate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL
—
CTx-1301 - Dexmethylphenidate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform
—
Drug–disease associations for CTx-1301 - Dexmethylphenidate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR
—
Cingulate Therapeutics company filings. U.S. Securities and Exchange Commission.
Details
Drug Info
Quick Facts
Modality
Small molecule
[2]
Highest Phase
Phase 3
[1]
Company
C
Cingulate Therapeutics
Related News